Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID06096688

Discovering New Targets for Hereditary and Sporadic Colorectal and Endometrial Cancer Risk Reduction

Led by Weill Medical College of Cornell University · Updated on 2025-09-04

1120

Participants Needed

1

Research Sites

30 weeks

Total Duration

On this page

Sponsors

W

Weill Medical College of Cornell University

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are collecting and storing data, tissue samples, and personal and family histories from patients being screened for colorectal cancer and endometrial cancer during routine clinical care. The study aims to discover new genetic mechanisms and proteins related to hereditary cancer syndromes to help develop targeted therapies and prevention strategies. It also focuses on understanding how the immune system can recognize and attack tumor cells carrying mutations. Participants include those with hereditary cancer syndromes undergoing endoscopy or surgical procedures, both with and without treatment using NSAIDs, as well as average-risk individuals undergoing routine lower gastrointestinal procedures. Tissue samples such as normal mucosa, polyps, adenocarcinomas, and blood are collected during standard care procedures like endoscopy, surgery, transvaginal ultrasound, hysteroscopy, and endometrial biopsy at Weill Cornell and New York Presbyterian Hospital. Participants provide informed consent to allow collection and storage of clinical data including demographics, medical history, and outcomes. Samples are processed and stored for future research. The study will monitor novel genetic predispositions, potential therapy targets, and immune responses over a period of seven years to create a valuable hereditary colorectal and endometrial cancer registry and tissue repository.

CONDITIONS

Brief Title

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo endoscopy or endometrial screening procedures
  • Individuals undergoing endoscopy, transvaginal ultrasound, or hysteroscopy for average-risk screening
  • Individuals diagnosed with colorectal or endometrial cancer coming for surgical treatment
  • Individuals coming for diagnostic testing, clinic visits, or treatment at Weill-Cornell Medicine/NYPH
  • Willingness and ability to sign informed consent
  • Ability to read and understand English, Spanish, or simplified Chinese
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit

Sample Collection

Duration - Ongoing throughout clinical procedures

Participants provide blood and tissue samples during routine clinical procedures such as endoscopy, transvaginal ultrasound, hysteroscopy, or surgery. These samples are collected for research to study genetic predisposition and cancer biology.

Samples collected during routine care visits and procedures

Long-term Monitoring

Duration - Up to 7 years

Participants are observed over time to facilitate discoveries related to hereditary and sporadic colorectal and endometrial cancer risk, including genetic and immune system studies.

Observation concurrent with routine clinical follow-up visits

Trial Site Locations

Total: 1 location

1

NYP/Weill Cornell Medicine

New York, New York, United States, 10065

Actively Recruiting

Loading map...

Research Team

S

Steven M Lipkin, MD, PhD

M

Melissa K Frey, MD, MS

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

6

Similar Trials

Phase 0/1 Study of Safety and Dose Finding of 177Lu-RAD204, ...

PDL1 Gene Mutation

Actively Recruiting

5 locations

A Phase 1/2a Study of the Safety, Tolerability, and Prelimin...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here